Cubist Systematic Strategies LLC Invests $1.06 Million in Neuronetics, Inc. $STIM

Key Points

• Cubist Systematic Strategies LLC acquired a new position in Neuronetics, purchasing 286,571 shares valued at approximately $1,055,000, making up about 0.44% of the company's stock.
• Canaccord Genuity Group has lowered its price target for Neuronetics from $8.00 to $7.00, while analysts maintain a consensus rating of "Buy".
• Neuronetics reported a quarterly earnings loss of ($0.15) per share, missing estimates, despite revenue of $38.11 million surpassed expectations.

Cubist Systematic Strategies LLC purchased a new stake in Neuronetics, Inc. (NASDAQ:STIM - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 286,571 shares of the company's stock, valued at approximately $1,055,000. Cubist Systematic Strategies LLC owned about 0.44% of Neuronetics at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. Ghisallo Capital Management LLC purchased a new position in shares of Neuronetics during the first quarter worth approximately $1,472,000. Gordian Capital Singapore Pte Ltd purchased a new stake in Neuronetics in the first quarter valued at about $90,000. MYDA Advisors LLC purchased a new stake in Neuronetics in the first quarter valued at about $110,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Neuronetics during the first quarter worth $212,000. Finally, FORA Capital LLC acquired a new stake in shares of Neuronetics during the first quarter worth $42,000. Institutional investors own 53.59% of the company's stock.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group decreased their target price on shares of Neuronetics from $8.00 to $7.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. One research analyst has rated the stock with a Buy rating, According to MarketBeat.com, Neuronetics currently has an average rating of "Buy" and an average price target of $7.00.

Neuronetics Stock Performance

Neuronetics stock traded down $0.24 during midday trading on Friday, hitting $3.22. 503,792 shares of the company's stock were exchanged, compared to its average volume of 1,246,379. Neuronetics, Inc. has a 12-month low of $0.52 and a 12-month high of $5.92. The company has a debt-to-equity ratio of 1.76, a quick ratio of 1.84 and a current ratio of 2.02. The stock has a market cap of $212.64 million, a price-to-earnings ratio of -2.85 and a beta of 1.28. The firm's 50 day simple moving average is $3.75 and its 200 day simple moving average is $3.97.

Neuronetics (NASDAQ:STIM - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.07). Neuronetics had a negative return on equity of 156.36% and a negative net margin of 43.47%.The firm had revenue of $38.11 million during the quarter, compared to analyst estimates of $36.80 million. Neuronetics has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts predict that Neuronetics, Inc. will post -1.13 EPS for the current year.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.